OMT Grants Unlimited Platform Access to CNA Development LLC

Oct 07 2013

PALO ALTO, California—Open Monoclonal Technology, Inc. (OMT), a leader in genetic engineering of animals for discovery of human therapeutic antibodies, today announced expansion of its ongoing collaboration with CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. (“Janssen”).  Following a preliminary collaboration on OmniRat® announced in December 2012, OMT has now granted Janssen licenses to use all its genetically engineered animals, OmniRat, OmniMouse® and OmniFlic™, for an unlimited number of targets and indications. Under the terms of the expanded agreement, Janssen will pay OMT annual platform access fees and success-based development and commercial milestone payments for each product derived from OMT’s antibody platforms.

Dr. Roland Buelow, Founder and CEO of OMT, said: “Unlimited, triple-platform access provides OMT’s partners with cost-efficient ability to create superior antibodies against some of the most challenging targets.  OMT expects to see more and more partners taking such broad access, which will make OMT a profitable biotech company without need for further private or public funding.”
OMT offers its collaborators both target-by-target and unlimited platform access. Target-by-target licensing allows the partners to use the technologies in a limited fashion and compare them to existing internal technologies, including humanization of animal-derived antibodies, optimization of display-derived antibodies, and alternative transgenic animal systems. Unlimited platform access provides a more cost effective long term alternative and gives OMT and its partners more chances at discovery and development of clinically-commercially successful therapeutic antibodies.

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for discovery of human therapeutic antibodies – naturally optimized human antibodies®.  OMT has created OmniRat®, the industry’s first fully human monoclonal antibody platform based on rats. It represents a novel and proprietary technology with unrestricted development options. OMT and Pfizer have
demonstrated that OmniRat has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as a wild-type animals make rat antibodies (Journal of Immunology 2013 Feb 15; 190(4):1481-90).

OmniMouse® is a transgenic mouse designed to complement OmniRat and further increase epitope coverage.  Both animals deliver antibodies with great affinity, specificity, expression, solubility and stability, yet with low or no immunogenicity or need for lead optimization. OmniFlic™ is the industry’s first engineered rat with a fixed light chain for development of human bispecific antibodies.
OMT’s antibody platforms have broad freedom to operate and use technology protected by new patents and patent applications. They are available for licensing worldwide for all targets and indications and are presently partnered with Merck KGaA, Pfizer, WuXi AppTec and other biopharmaceutical companies.

For more information, please visit OMT’s web site or contact Brian Lundstrom, OMT’s Chief Business Officer, at phone +1-775-420-7750 or E-mail: [email protected]